{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:27:30Z","timestamp":1773059250062,"version":"3.50.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The Clinical Pharmacology Quality Assurance (CPQA) program provides semiannual proficiency testing (PT) of antiretroviral analytes for 11 US and international clinical pharmacology laboratories (CPLs) to ensure interlaboratory comparability. In this article, we provide estimates of the main sources of variability and assess the accuracy of the algorithm for the assessment of performance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Descriptive statistics are reported from 13 PT rounds from 2010 to 2016. Eight of the most common antiretroviral analytes were examined. Variance components analysis was used to rank the relative contributions of CPLs, antiretroviral analyte, and concentration category (low, medium, and high) to bias and variability using mixed models. Binary classification metrics of the PT assessment algorithm are calculated in comparison with a model using 95% prediction limits around estimated regression equations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>CPLs provided 4109 reported concentrations of 65 unique samples for each of the 8 antiretroviral analytes across 13 PT rounds. Individual CPL accounted for the greatest amount of total variability (4.4%). Individual CPL and analyte combination (interaction) accounted for the greatest amount of bias (8.1%). Analyte alone accounted for 0.5% or less for total variability and bias. Overall, using a \u00b120% acceptance window around the final target, 97% of individual reported concentrations were scored acceptable, and 96% of antiretroviral\/round scores were deemed satisfactory. Comparison with the regression model gave 100% sensitivity but only 34.47% specificity. Narrowing the acceptance window to \u00b115% improved specificity to 84.47% while maintaining a 99.17% sensitivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The current CPQA PT scoring algorithm that use a \u00b120% acceptance window seems to suffer from a low specificity and may be too lenient. A stricter \u00b115% acceptance window would increase specificity and overall accuracy while lowering the overall pass rate by only 3%.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000612","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T21:40:05Z","timestamp":1551822005000},"page":"452-458","source":"Crossref","is-referenced-by-count":7,"title":["Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for Antiretrovirals"],"prefix":"10.1097","volume":"41","author":[{"given":"Richard W.","family":"Browne","sequence":"first","affiliation":[{"name":"Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Frontier Science Technology and Research Foundation, Amherst, New York; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Frontier Science Technology and Research Foundation, Amherst, New York; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene R.","family":"Taylor","sequence":"additional","affiliation":[{"name":"HIV Clinical Pharmacology Research Program, Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"DiFrancesco","sequence":"additional","affiliation":[{"name":"HIV Clinical Pharmacology Research Program, Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[{"name":"HIV Clinical Pharmacology Research Program, Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1373\/clinchem.2011.168641","article-title":"Proficiency testing\/external quality assessment: current challenges and future directions","volume":"57","author":"Miller","year":"2011","journal-title":"Clin Chem."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/FTD.0b013e31828f5088","article-title":"Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories","volume":"35","author":"DiFrancesco","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11481-017-9761-6","article-title":"Differential effects of antiretroviral drugs on neurons in vitro: roles for oxidative stress and integrated stress response","volume":"13","author":"Stern","year":"2018","journal-title":"J Neuroimmune Pharmacol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1351\/pac200678010145","article-title":"The international harmonized protocol for the proficiency testing of analytical chemistry laboratories (IUPAC Technical Report)","volume":"78","author":"Thompson","year":"2006","journal-title":"Pure Appl Chem."},{"key":"R5-20230814","first-page":"7002","article-title":"Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)-HCFA: final rule with comment period","volume":"57","year":"1992","journal-title":"Fed Reg."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/clinchem\/46.1.89","article-title":"Causes of unsatisfactory performance in proficiency testing","volume":"46","author":"Jenny","year":"2000","journal-title":"Clin Chem."},{"key":"R7-20230814","first-page":"557","article-title":"Selection and interpretation of diagnostic tests and procedures. Principles and applications","volume":"94","author":"Griner","year":"1981","journal-title":"Ann Intern Med."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.chroma.2014.03.077","article-title":"Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect","volume":"1353","author":"Gonz\u00e1lez","year":"2014","journal-title":"J Chromatogr A."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/FTD.0b013e31820fa528","article-title":"The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program","volume":"33","author":"Burger","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/FTD.0000000000000089","article-title":"Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma\/serum","volume":"36","author":"Burger","year":"2014","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:20:41Z","timestamp":1692051641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000612","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}